Skip to Content

Data Mine: Treating Cancer

New hopes for combating the disease
September 1, 2005

Cancer is the second-leading cause of death in the United States, surpassed only by heart disease. But recent technological developments offer the hope of new and better ways to combat the disease.

For many of the most pervasive types of cancer, about half of the drug candidates furthest along in the research pipeline use approaches other than that of traditional cytotoxic drugs, which work by killing cells or preventing their division.

With continuing advances in the development of therapies like monoclonal antibodies and tumor vaccines, biotechnology should account for a growing portion of the cancer drug market, which may reach $80 billion a year by 2009.

As costs soar and reimbursement wanes, though, many patients are unlikely to reap the benefits of some of the most promising of these developments.  

Keep Reading

Most Popular

Here’s how a Twitter engineer says it will break in the coming weeks

One insider says the company’s current staffing isn’t able to sustain the platform.

Technology that lets us “speak” to our dead relatives has arrived. Are we ready?

Digital clones of the people we love could forever change how we grieve.

How to befriend a crow

I watched a bunch of crows on TikTok and now I'm trying to connect with some local birds.

Starlink signals can be reverse-engineered to work like GPS—whether SpaceX likes it or not

Elon said no thanks to using his mega-constellation for navigation. Researchers went ahead anyway.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.